---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-017870"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:55:13.650375+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports preclinical flu vaccine data with Infectimune at IMMUNOLOGY2025

## Summary
- Infectimune-based flu vaccine elicited multifunctional, influenza-specific CD4 T cells with cytotoxic characteristics in preclinical studies.
- Preclinical ferret studies showed neutralization of H3N2 influenza strains from 2014 to 2021 using COBRA antigens.
- Studies were funded by NIAID's CIVR-HRP and presented by Dr. Sant (U of Rochester) and Dr. Allen (Cleveland Clinic).
- Company reaffirms focus on VERSATILE-003 Phase 3 trial for Versamune HPV in HPV16-positive HNSCC.

## SEC filing metadata
- accession: 0001140361-25-017870
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125017870/0001140361-25-017870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125017870/ef20048584_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-017870
- JSON: https://secwatch.observer/filing/0001140361-25-017870.json
- Plain text: https://secwatch.observer/filing/0001140361-25-017870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.